ATE164082T1 - Zielgesuchte radioaktive immunoreagenzien - Google Patents
Zielgesuchte radioaktive immunoreagenzienInfo
- Publication number
- ATE164082T1 ATE164082T1 AT91920573T AT91920573T ATE164082T1 AT E164082 T1 ATE164082 T1 AT E164082T1 AT 91920573 T AT91920573 T AT 91920573T AT 91920573 T AT91920573 T AT 91920573T AT E164082 T1 ATE164082 T1 AT E164082T1
- Authority
- AT
- Austria
- Prior art keywords
- targeted radioactive
- radioactive immunoreagents
- immunoreagents
- targeted
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6887—Antibody-chelate conjugates using chelates for therapeutic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1054—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
- C07D213/77—Hydrazine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61086190A | 1990-11-08 | 1990-11-08 | |
US07/784,333 US5367080A (en) | 1990-11-08 | 1991-10-29 | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE164082T1 true ATE164082T1 (de) | 1998-04-15 |
Family
ID=27086372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT91920573T ATE164082T1 (de) | 1990-11-08 | 1991-11-07 | Zielgesuchte radioaktive immunoreagenzien |
Country Status (21)
Country | Link |
---|---|
US (4) | US5367080A (de) |
EP (1) | EP0624097B1 (de) |
JP (1) | JP3292301B2 (de) |
KR (1) | KR930701974A (de) |
AT (1) | ATE164082T1 (de) |
AU (2) | AU667030B2 (de) |
BR (1) | BR9107074A (de) |
CA (1) | CA2095123A1 (de) |
DE (1) | DE69129127T2 (de) |
DK (1) | DK0624097T3 (de) |
ES (1) | ES2113892T3 (de) |
FI (1) | FI932083A (de) |
GR (1) | GR3026713T3 (de) |
HU (1) | HUT67298A (de) |
IE (1) | IE913907A1 (de) |
MX (1) | MX9101999A (de) |
NO (1) | NO931631L (de) |
NZ (1) | NZ240521A (de) |
PT (1) | PT99460B (de) |
TW (1) | TW201271B (de) |
WO (1) | WO1992008494A2 (de) |
Families Citing this family (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5367080A (en) * | 1990-11-08 | 1994-11-22 | Sterling Winthrop Inc. | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
KR950701229A (ko) * | 1992-05-07 | 1995-03-23 | 로이스 이. 밈스 | 착화제와 타게팅 면역시약 |
KR950703582A (ko) * | 1992-10-14 | 1995-09-20 | 조이스 이. 마임스 | 킬레이트화 중합체(chelating polymers) |
WO1994014440A1 (en) * | 1992-12-28 | 1994-07-07 | Taisho Pharmaceutical Co., Ltd. | Pharmaceutical use of terpyridine derivative |
US5760191A (en) * | 1993-02-05 | 1998-06-02 | Nycomed Imaging As | Macrocyclic complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions and methods |
EP0691981A1 (de) * | 1993-03-10 | 1996-01-17 | The Wellcome Foundation Limited | Auf tumor zielende l-enantiomere oligonucleotidkonjugate aus immunreagentien und radionuclidchelaten |
US5744119A (en) * | 1993-05-11 | 1998-04-28 | Sterling Winthrop | Preparation of a radioconjugate formulation |
US5559214A (en) | 1993-05-28 | 1996-09-24 | Sterling Winthrop Inc. | Unsymmetrical complexing agents and targeting immunoreagents useful in thearpeutic and diagnostic compositions and methods |
JPH09501147A (ja) * | 1993-06-07 | 1997-02-04 | ザ・ウエルカム・ファウンデーション・リミテッド | モノアミンオキシダーゼを使用する免疫反応性試薬 |
DE19505960A1 (de) * | 1995-02-21 | 1996-08-22 | Deutsches Krebsforsch | Konjugat zur individuellen Dosierung von Arzneimitteln |
US5562626A (en) * | 1995-09-11 | 1996-10-08 | Sanpietro; Joseph A. | Safety syringe |
AUPO066096A0 (en) * | 1996-06-26 | 1996-07-18 | Peptide Delivery Systems Pty Ltd | Oral delivery of peptides |
US6656481B1 (en) | 1996-09-06 | 2003-12-02 | Mitsubishi Chemical Corporation | Vaccinal preparations |
AU9452198A (en) * | 1997-10-15 | 1999-05-17 | Nycomed Imaging As | Complexing agents and targeting immunoreagents |
AU2530199A (en) * | 1998-02-06 | 1999-08-23 | Nycomed Imaging As | Targeting immunoreagents useful in therapeutic and diagnostic compositions and methods |
DE19911329A1 (de) * | 1998-03-27 | 2000-09-21 | Benes Ivan Friedrich | Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung |
WO1999049893A1 (en) * | 1998-03-31 | 1999-10-07 | Trustees Of Boston University | Methods for designing molecular conjugates and compositions thereof |
US6314314B1 (en) | 1999-01-14 | 2001-11-06 | Seth J. Karp | Method for locating an internal bleeding site in a human body |
CA2376245A1 (en) * | 1999-07-29 | 2001-02-08 | Dyax Corp. | Binding moieties for fibrin |
EP1272507B1 (de) * | 2000-04-12 | 2005-06-29 | Amersham Health AS | Integrinbindende peptidderivate |
NO20004795D0 (no) * | 2000-09-26 | 2000-09-26 | Nycomed Imaging As | Peptidbaserte forbindelser |
US6727167B2 (en) * | 2000-10-13 | 2004-04-27 | Emcore Corporation | Method of making an aligned electrode on a semiconductor structure |
US7009040B2 (en) * | 2003-01-21 | 2006-03-07 | Arius Research, Inc. | Cancerous disease modifying antibodies |
US6984373B2 (en) * | 2000-12-23 | 2006-01-10 | Dyax Corp. | Fibrin binding moieties useful as imaging agents |
AU2002313616A1 (en) | 2001-07-10 | 2003-01-29 | Amersham Health As | Peptide-based compounds for targeting intergin receptors |
CA2471363C (en) | 2001-12-21 | 2014-02-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US7794693B2 (en) | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
WO2004065621A1 (en) | 2002-03-01 | 2004-08-05 | Dyax Corp. | Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
US7211240B2 (en) | 2002-03-01 | 2007-05-01 | Bracco International B.V. | Multivalent constructs for therapeutic and diagnostic applications |
ES2506142T3 (es) | 2002-03-01 | 2014-10-13 | Dyax Corp. | Péptidos de unión a KDR y a VEGF/KDR y su uso en diagnóstico |
EP2070949B1 (de) * | 2002-06-10 | 2013-01-16 | Vaccinex, Inc. | C35-Antikörper und ihre Verwendung zur Behandlung von Krebs |
US7226577B2 (en) | 2003-01-13 | 2007-06-05 | Bracco Imaging, S. P. A. | Gastrin releasing peptide compounds |
US7468254B2 (en) * | 2003-01-21 | 2008-12-23 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
US7393531B2 (en) * | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
EP1603935A4 (de) | 2003-03-03 | 2007-03-21 | Dyax Corp | SPEZIFISCH AN HGF-REZEPTOR (cMet) BINDENDE PEPTIDE UND DEREN VERWENDUNG |
AU2004259028C1 (en) * | 2003-07-24 | 2009-12-24 | Bracco Imaging S.P.A. | Stable radiopharmaceutical compositions and methods for preparation |
EP2962699A3 (de) | 2003-12-01 | 2016-04-06 | Immunomedics Inc. | Verbessertes verfahren zur herstellung von konjugaten von proteinen und chelatbildnern |
JP5042631B2 (ja) * | 2003-12-04 | 2012-10-03 | バクシネックス インコーポレーティッド | アポトーシス腫瘍細胞上に露出した細胞内抗原をターゲッティングすることによって腫瘍細胞を死滅させる方法 |
WO2005100340A2 (en) * | 2004-04-13 | 2005-10-27 | Icagen, Inc. | Polycyclic pyridines as potassium ion channel modulators |
US20060024229A1 (en) * | 2004-07-29 | 2006-02-02 | Seth Karp | Method and product for locating an internal bleeding site |
US20100034748A1 (en) * | 2008-08-07 | 2010-02-11 | Guizhi Li | Molecular imaging probes based on loaded reactive nano-scale latex |
MX2008002233A (es) * | 2005-08-16 | 2008-03-27 | Univ North Carolina At Wilming | Ligandos para iones de metal y metodos para elaborar y usar los mismos. |
US20090098057A1 (en) * | 2007-10-16 | 2009-04-16 | Shiying Zheng | Silica-cored carrier particle |
US20070179094A1 (en) | 2006-01-31 | 2007-08-02 | Bayer Schering Pharma Ag | Modulation of MDL-1 activity for treatment of inflammatory disease |
US20080167544A1 (en) * | 2006-12-01 | 2008-07-10 | Cold Spring Diagnostics, Inc. | Compositions And Methods For Locating An Internal Bleeding Site |
CN101558081B (zh) | 2006-12-11 | 2014-08-20 | 伯拉考成像股份公司 | 用于诊断和治疗应用的纤维蛋白结合肽缀合体 |
US8906354B2 (en) | 2007-02-28 | 2014-12-09 | Bruker Biospin Corporation | Loaded latex optical molecular imaging probes containing lipophilic large stokes shift dyes |
EP2005970A1 (de) | 2007-06-22 | 2008-12-24 | Berlin Science Partners GmbH i.V. | Bildgebende Diagnostik durch Kombination von Kontrastmitteln |
US8637026B2 (en) * | 2007-12-26 | 2014-01-28 | Vaccinex, Inc. | Anti-C35 antibody combination therapies and methods |
EP2100900A1 (de) | 2008-03-07 | 2009-09-16 | Universitätsspital Basel | Bombesin-analoge Peptid-antagonistische Konjugate |
EP2147684A1 (de) | 2008-07-22 | 2010-01-27 | Bracco Imaging S.p.A | Selektiv gegen Metallproteasen wirkende Diagnosemittel |
US20120045393A1 (en) | 2009-03-17 | 2012-02-23 | Linder Karen E | Lhrh-ii peptide analogs |
AR075900A1 (es) | 2009-03-19 | 2011-05-04 | Wyeth Llc | Metodos para la preparacion de acidos (2-(8,9-dioxo-2,6-diazabiciclico (5.2.0) non-1(7)-en-2-il)etil) fosfonico y sus precursores. |
WO2010121133A2 (en) | 2009-04-17 | 2010-10-21 | The General Hospital Corporation | Multimodal imaging of fibrin |
WO2011030566A1 (en) * | 2009-09-14 | 2011-03-17 | Eisai R&D Management Co., Ltd. | Phenanthroline derivatives and their use as ligands |
FR2969999B1 (fr) * | 2011-01-03 | 2013-02-08 | Commissariat Energie Atomique | Conjugue, son procede de preparation et ses utilisations |
US9187690B2 (en) * | 2011-03-11 | 2015-11-17 | B.R.A.H.M.S. Gmbh | Rare earth metal complex having phenanthroline compound as ligand |
WO2013048832A1 (en) | 2011-09-29 | 2013-04-04 | Ge Healthcare Limited | 18 f - labelled 6 - ( 2 - fluoroethoxy) - 2 - naphthaldehyde for detecting cancer stem cells |
EP2740726A1 (de) | 2012-12-07 | 2014-06-11 | 3B Pharmaceuticals GmbH | Neurotensin-Rezeptorligande |
AU2014228815B2 (en) | 2013-03-15 | 2019-04-18 | The Regents Of The University Of California | Peptides having reduced toxicity that stimulate cholesterol efflux |
WO2015171543A1 (en) | 2014-05-05 | 2015-11-12 | California Institute Of Technology | Mutant akt-specific capture agents, compositions, and methods of using and making |
EP3154638A1 (de) | 2014-06-10 | 2017-04-19 | 3B Pharmaceuticals GmbH | Konjugat mit einem neurotensinrezptorliganden und verwendung davon |
EP2954934A1 (de) | 2014-06-11 | 2015-12-16 | 3B Pharmaceuticals GmbH | Konjugat aus einem Neurotensinrezeptorliganden und Verwendung davon |
EP2954933A1 (de) | 2014-06-10 | 2015-12-16 | 3B Pharmaceuticals GmbH | Konjugat mit einem Neurotensinrezptorligand |
CN108290927B (zh) | 2015-07-15 | 2022-06-24 | 加州理工学院 | Il-17f-特异性捕获剂、组合物以及使用和制造的方法 |
IL260957B2 (en) | 2016-02-09 | 2023-11-01 | Bracco Suisse Sa | Chimeric, Recombinant Protein Glycoprotein Selectin-P Ligand-1 (PSGL-1) Conjugates, Preparations Containing Them and Uses Thereof |
CN115109120A (zh) | 2016-04-04 | 2022-09-27 | 英蒂分子公司 | Cd8-特异性捕获剂、组合物及使用和制备方法 |
EP3279197A1 (de) | 2016-08-03 | 2018-02-07 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Diagnose, behandlung und vorbeugung von zuständen, die mit dem neurotensin-rezeptor verbunden sind |
US11884707B2 (en) | 2016-09-29 | 2024-01-30 | Regeneron Pharmaceuticals, Inc. | Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same |
US11358982B2 (en) | 2016-11-01 | 2022-06-14 | Ohio State Innovation Foundation | Methods for the iodination of biomolecules |
WO2018232345A1 (en) | 2017-06-15 | 2018-12-20 | Indi Molecular, Inc. | Il-17f and il-17a-specific capture agents, compositions, and methods of using and making |
WO2020097531A1 (en) | 2018-11-08 | 2020-05-14 | Indi Molecular, Inc. | Theranostic capture agents, compositions, and methods of using and making |
US20200291391A1 (en) | 2019-03-12 | 2020-09-17 | Indi Molecular, Inc. | Cross-linked epitopes and methods of use thereof |
WO2020236969A1 (en) | 2019-05-20 | 2020-11-26 | Indi Molecular, Inc. | Compositions and methods relating to detection, inhibition, and imaging of indoleamine 2,3-dioxygenase 1 (ido1) |
EP3763726A1 (de) | 2019-07-08 | 2021-01-13 | 3B Pharmaceuticals GmbH | Verbindungen mit fibroblasten-aktivierendem proteinligand und deren verwendung |
BR112022000144A2 (pt) | 2019-07-08 | 2022-02-22 | 3B Pharmaceuticals Gmbh | Compostos que compreendem um ligante de proteína de ativação de fibroblastos e uso dos mesmos |
US11414460B2 (en) | 2019-07-19 | 2022-08-16 | Institute For Systems Biology | KRAS-specific capture agents, compositions, and methods of making and using |
WO2022098743A1 (en) | 2020-11-03 | 2022-05-12 | Indi Molecular, Inc. | Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1) |
WO2022098745A1 (en) | 2020-11-03 | 2022-05-12 | Indi Molecular, Inc. | Compositions, delivery systems, and methods useful in tumor therapy |
WO2022123462A1 (en) | 2020-12-09 | 2022-06-16 | 3B Pharmaceuticals Gmbh | Radiolabelled prostate specific membrane antigen (psma) inhibitors and use thereof |
EP4050018A1 (de) | 2021-01-07 | 2022-08-31 | 3B Pharmaceuticals GmbH | Verbindungen mit fibroblasten-aktivierendem proteinligand und deren verwendung |
MX2023007869A (es) | 2021-01-07 | 2023-09-22 | 3B Pharmaceuticals Gmbh | Compuestos que comprenden un ligando de proteina de activacion de fibroblasto y uso del mismo. |
EP4122499A1 (de) | 2021-07-23 | 2023-01-25 | 3B Pharmaceuticals GmbH | Inhibitoren des fibroblastenaktivierungsproteins und verwendung davon |
WO2023111350A2 (en) | 2021-12-17 | 2023-06-22 | 3B Pharmaceuticals Gmbh | Carbonic anhydrase ix ligands |
WO2024052431A1 (en) | 2022-09-07 | 2024-03-14 | 3B Pharmaceuticals Gmbh | Prostate specific membrane antigen (psma) ligands and use thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4670572A (en) * | 1981-07-01 | 1987-06-02 | Eastman Kodak Company | Phenolic fluorescent labels |
US4637988A (en) * | 1981-07-01 | 1987-01-20 | Eastman Kodak Company | Fluorescent labels for immunoassay |
US4794191A (en) * | 1981-07-01 | 1988-12-27 | Eastman Kodak Company | Fluorescent chelates |
US4801722A (en) * | 1981-07-01 | 1989-01-31 | Eastman Kodak Company | Coumarin chelates |
US4859777A (en) * | 1981-07-01 | 1989-08-22 | Eastman Kodak Company | Terpyridine chelating agents |
US4837169A (en) * | 1981-07-01 | 1989-06-06 | Eastman Kodak Company | Polypyridine Fluorescent labels for immunoassay |
US4767611A (en) * | 1984-07-03 | 1988-08-30 | Gordon Robert T | Method for affecting intracellular and extracellular electric and magnetic dipoles |
DE3580420D1 (de) * | 1984-08-13 | 1990-12-13 | Hsc Res Dev Corp | 1,10-phenanthrolin-2,9-dicarbonsaeure-derivate und deren verwendung fuer fluoreszens-immunoassay. |
DK365785A (da) * | 1984-09-17 | 1986-03-18 | Hoffmann La Roche | Metalcomplexer |
US5075447A (en) * | 1984-09-17 | 1991-12-24 | Hoffmann-La Roche Inc. | Ruthenium complexes useful as carriers for immunologically active materials |
US4761481A (en) * | 1985-03-18 | 1988-08-02 | Baxter Travenol Laboratories, Inc. | Substituted pyridine derivatives |
SE8502573D0 (sv) * | 1985-05-23 | 1985-05-23 | Jouko Kanakre | Fluorescent lanthanide chelates useful as labels of physiologically active materials |
WO1987007955A1 (en) * | 1986-06-17 | 1987-12-30 | Baxter Travenol Laboratories, Inc. | Homogeneous fluoroassay methods employing fluorescent background rejection and water-soluble rare earth metal chelate fluorophores |
ZA877727B (en) * | 1986-10-17 | 1988-06-29 | Cytogen Corp | Method for preparation of protein-chelator-metal ion compositions suitable for injection |
SE8702824L (sv) * | 1987-07-10 | 1989-01-11 | Wallac Oy | Metall-kelaterande 2,6-disubstituerade pyridinfoereningar och deras anvaendning |
US5032677A (en) * | 1987-11-06 | 1991-07-16 | Baxter International Inc. | Fluorescent poly(arylpyridine) rare earth chelates |
JPH082878B2 (ja) * | 1988-02-12 | 1996-01-17 | 富士写真フイルム株式会社 | 4’−アルコキシ−2,2’:6’,2〃−デルピリジン誘導体及びその金属錯体 |
SE8800613D0 (sv) * | 1988-02-23 | 1988-02-23 | Wallac Oy | A novel spectrofluorometric method and compounds that are of value for the method |
US5202423A (en) * | 1988-07-08 | 1993-04-13 | Wallac Oy | Terpyridine derivatives |
SE8802575D0 (sv) * | 1988-07-08 | 1988-07-08 | Wallac Oy | Terpyridine derivatives |
FR2644785B1 (fr) * | 1989-03-24 | 1991-07-05 | Guerbet Sa | Nouveaux ligands macrocycliques azotes, procede de preparation, complexes metalliques formes par ces ligands et composition de diagnostic les contenant |
GB8927503D0 (en) * | 1989-12-04 | 1990-02-07 | Kronem Systems Inc | Enzyme-amplified lanthanide chelate luminescence |
GB9001245D0 (en) * | 1990-01-19 | 1990-03-21 | Salutar Inc | Compounds |
US5367080A (en) * | 1990-11-08 | 1994-11-22 | Sterling Winthrop Inc. | Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods |
-
1991
- 1991-10-29 US US07/784,333 patent/US5367080A/en not_active Expired - Lifetime
- 1991-11-07 DE DE69129127T patent/DE69129127T2/de not_active Expired - Lifetime
- 1991-11-07 BR BR919107074A patent/BR9107074A/pt not_active Application Discontinuation
- 1991-11-07 JP JP50016592A patent/JP3292301B2/ja not_active Expired - Lifetime
- 1991-11-07 EP EP91920573A patent/EP0624097B1/de not_active Expired - Lifetime
- 1991-11-07 CA CA002095123A patent/CA2095123A1/en not_active Abandoned
- 1991-11-07 DK DK91920573T patent/DK0624097T3/da active
- 1991-11-07 KR KR1019930701386A patent/KR930701974A/ko not_active IP Right Cessation
- 1991-11-07 AU AU90291/91A patent/AU667030B2/en not_active Expired
- 1991-11-07 HU HU9301328A patent/HUT67298A/hu unknown
- 1991-11-07 ES ES91920573T patent/ES2113892T3/es not_active Expired - Lifetime
- 1991-11-07 WO PCT/US1991/008253 patent/WO1992008494A2/en active IP Right Grant
- 1991-11-07 AT AT91920573T patent/ATE164082T1/de active
- 1991-11-08 PT PT99460A patent/PT99460B/pt not_active IP Right Cessation
- 1991-11-08 NZ NZ240521A patent/NZ240521A/en unknown
- 1991-11-08 MX MX9101999A patent/MX9101999A/es unknown
- 1991-11-08 IE IE390791A patent/IE913907A1/en unknown
-
1992
- 1992-01-07 TW TW081100086A patent/TW201271B/zh active
-
1993
- 1993-05-05 NO NO93931631A patent/NO931631L/no unknown
- 1993-05-07 FI FI932083A patent/FI932083A/fi not_active Application Discontinuation
-
1994
- 1994-08-08 US US08/287,381 patent/US5523402A/en not_active Expired - Lifetime
-
1995
- 1995-01-19 US US08/375,276 patent/US5707603A/en not_active Expired - Lifetime
- 1995-12-15 US US08/573,377 patent/US5677445A/en not_active Expired - Lifetime
-
1996
- 1996-06-07 AU AU55835/96A patent/AU5583596A/en not_active Abandoned
-
1998
- 1998-04-23 GR GR980400901T patent/GR3026713T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU9029191A (en) | 1992-06-11 |
US5707603A (en) | 1998-01-13 |
MX9101999A (es) | 1992-06-01 |
WO1992008494A2 (en) | 1992-05-29 |
DE69129127D1 (de) | 1998-04-23 |
US5523402A (en) | 1996-06-04 |
US5677445A (en) | 1997-10-14 |
NZ240521A (en) | 1995-01-27 |
GR3026713T3 (en) | 1998-07-31 |
ES2113892T3 (es) | 1998-05-16 |
KR930701974A (ko) | 1993-09-08 |
JP3292301B2 (ja) | 2002-06-17 |
CA2095123A1 (en) | 1992-05-09 |
AU667030B2 (en) | 1996-03-07 |
DE69129127T2 (de) | 1998-10-08 |
HU9301328D0 (en) | 1993-10-28 |
IE913907A1 (en) | 1992-05-20 |
AU5583596A (en) | 1996-08-01 |
PT99460B (pt) | 1999-02-26 |
US5367080A (en) | 1994-11-22 |
EP0624097B1 (de) | 1998-03-18 |
DK0624097T3 (da) | 1998-10-19 |
TW201271B (de) | 1993-03-01 |
NO931631L (no) | 1993-06-23 |
PT99460A (pt) | 1992-09-30 |
FI932083A0 (fi) | 1993-05-07 |
WO1992008494A3 (en) | 1993-07-08 |
NO931631D0 (no) | 1993-05-05 |
HUT67298A (en) | 1995-03-28 |
FI932083A (fi) | 1993-07-02 |
BR9107074A (pt) | 1993-09-21 |
EP0624097A1 (de) | 1994-11-17 |
JPH06501703A (ja) | 1994-02-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE164082T1 (de) | Zielgesuchte radioaktive immunoreagenzien | |
DK0622440T4 (da) | Fosforescerende lysstof | |
BR1100956A (pt) | Composto | |
DE69122557T2 (de) | Bilderzeugung | |
DE3587102T2 (de) | Superstrahlungslichtquelle. | |
DE69411520T2 (de) | Röntgenröhren | |
DE69128750D1 (de) | Lichtempfindliches Bauelement | |
DE69211751D1 (de) | Strahlungstechnologie | |
DE69110894T2 (de) | Feuchtigkeitsfester film. | |
FI910821A (fi) | Naolar omfattande suturfoerpackning. | |
DE69128751T2 (de) | Lichtempfindliches Bauelement | |
MA22092A1 (fr) | Boucliers parasismiques | |
DK0472379T3 (da) | Rørkoblinger | |
ATA112891A (de) | Dichloranilinverbindung | |
KR920009707U (ko) | 커플링 슬리이브 | |
DK283290A (da) | Koblingsorgan | |
DE69119276T2 (de) | Nah-Bildverstärker | |
DE69100445T2 (de) | Thiosulfatfixierlösungen. | |
DE69118300D1 (de) | Röntgenbildröhre | |
ATE95322T1 (de) | Thiosulfatfixierloesungen. | |
NO925056D0 (no) | Bisheterocyklisk forbindelse | |
BR1100710A (pt) | Composto | |
DK238590D0 (da) | Direct immuno filtertechnique | |
KR920005315U (ko) | 음극선관 | |
KR920010350U (ko) | 음극선관 |